Skip header and navigation

21 records – page 1 of 2.

Date Research Question / Title Unique ID Research Team
October 29, 2021 Long COVID: What does it mean for the healthcare system and programs to deal with it? EOC021901v2 RR EOC
October 7, 2021 What is the current evidence and recommendations regarding COVID-19 vaccine booster shots (exceeding 2 doses) for the general population? EOC210902 RR EOC
July 12, 2021 What are long COVID's demands on the healthcare system, and its severity of the illness? EPM210602 RR Epidemiology & Modelling
July 9, 2021 What is the incidence and duration of Long COVID cases? EPM210601 RR Epidemiology & Modelling
April 21, 2021 What are the risks or benefits of extended intervals between doses of COVID-19 vaccines compared to recommended dosing in extremely vulnerable populations? EOC210302 RR EOC
April 6, 2021 How to deliver remote ICU care for COVID-19 patients to avoid/prevent transfer from smaller communities to tertiary care hospitals CC210301 RR Critical Care
February 27, 2021 What is the final disposition of post-COVID patients who require chronic ventilation in the ICU? CC011101 RR Critical Care
January 22, 2021 What are the differences in the clinical course of COVID-19 between patients undergoing chemotherapy and otherwise healthy individuals? [Update] EOC062201v2 RR EOC
January 13, 2021 What are the outcomes of ECMO and COVID, particularly in small centers? EOC011101 RR EOC
December 9, 2020 What are the predictors of mortality in hospitalized COVID-19 patients? CC120402 RR Critical Care
November 25, 2020 Are probiotics effective for prevention or therapy of respiratory tract infections in all ages? EOC111201 RR EOC
November 2, 2020 What is the risk of reinfection from COVID-19? [Update] EOC032401v3 RR EOC
September 29, 2020 What is the evidence that runny nose or sneezing are symptoms of COVID-19? EOC092401 RR EOC
May 22, 2020 In similar jurisdictions experiencing the COVID-19 pandemic, what is the proportion of patients receiving non-invasive ventilation versus those receiving intermittent mandatory ventilation? EOC052102 RR EOC
May 19, 2020 What are the risk factors for severity and death associated with COVID-19? EPM050901 RR Epidemiology & Modelling
May 19, 2020 What is the relationship between antibody development and viral shedding and infectiousness? [Update] LAB041601v2 RR Laboratory
May 11, 2020 What percentage of COVID-19 patients have hyposmia or anosmia? EOC033102 RR EOC
May 8, 2020 What proportion of disease transmission is due to asymptomatic, pre-symptomatic and symptomatic cases? [Update] LAB040701v2 RR Laboratory
April 15, 2020 At what time in the disease timeline of COVID-19 do antibodies develop? LAB041402 RR Laboratory
April 11, 2020 Is the IgM or IgG immune response protective? LAB040803 RR Laboratory

21 records – page 1 of 2.